
Insights into COVID-19’s Origins, Recursion Reverses Course, and AACR Stands Up for Cancer Research
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
Acerca de esta escucha
The exact origins of SARS-CoV-2 are still something of a mystery, but new research may bring scientists one step closer to an explanation for how the virus reached Wuhan. Also in the episode, we dive into GEN’s coverage of the annual AACR meeting including how the community is navigating massive research budget cuts. Then we discuss a potential colorectal cancer therapy using CRISPR-edited tumor infiltrating lymphocytes and a method for delivering protein therapies and gene editors using engineered vesicles. Lastly, in business news, Recursion rethinks its pipeline, the FDA gives Abeona’s gene therapy a chance, and Bristol Myers Squibb execs open up on artificial intelligence.
Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Julianna LeMieux, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
AACR 2025: A Video Update from Chicago
By Julianna LeMieux, PhD and Damian Doherty, GEN, April 29, 2025
Hope and Headwinds at AACR in Chicago
By Damian Doherty, GEN, April 29, 2025
Senator Tammy Baldwin Supports Science in AACR Speech
By Julianna LeMieux, PhD, GEN, April 29, 2025
CRISPR-Edited TILs Fight Advanced Colorectal Cancer in Patients
By GEN, May 4, 2025
Engineered Extracellular Vesicles Could Deliver Gene Editors, Therapeutic Proteins to Cells
By GEN, April 30, 2025
SARS-CoV-2 Likely Spread Through Wildlife Trade, Not Bat Migration
By GEN, May 7, 2025
Chatting with Author David Quammen about SARS-CoV-2 Will Leave You “Breathless”
Originally aired: November 16, 2022
Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus
By Alex Philippidis, GEN Edge, May 5, 2025
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy
By Alex Philippidis, GEN Edge, May 4, 2025
Predict First: BMS Executives Discuss Company’s AI Approach
By Alex Philippidis, GEN Edge, March 26, 2025
Hosted on Acast. See acast.com/privacy for more information.